Latest News and Press Releases

Yale-linked platform lists LSLRCC, advancing climate adaptation, SDG 6 and SDG 13, and transparent drinking water infrastructure planning

HH Red Stone ranks Top 10 in J Turner Research’s 2025 ORA Power Ranking; The Haven on College also earned Elite 1% conventional property recognition.

New York, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) has awarded a grant of $917,027 to Yale University to establish the National Methadone Access and...

HH Group acquires College & Crown steps away from Yale University and rebrands the property as The Haven to enhance comfort and community.

Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study

60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development

Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.